Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 137240
Corporate User License Price USD 6000
Corporate User License Price INR 411720
Site License Price USD 4000
Site License Price INR 274480
Request a Quote

Report Title

rectal cancer-pipeline review, h2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

rectal cancer-pipeline review, h2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

rectal cancer-pipeline review, h2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

rectal cancer-pipeline review, h2 2017



Executive Summary

Rectal Cancer-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer-Pipeline Review, H2 2017, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 4 and 1 respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rectal Cancer-Overview

Rectal Cancer-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rectal Cancer-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rectal Cancer-Companies Involved in Therapeutics Development

AbbVie Inc

Advaxis Inc

Eisai Co Ltd

GlaxoSmithKline Plc

Karyopharm Therapeutics Inc

Madrigal Pharmaceuticals Inc.

NewLink Genetics Corp

Peregrine Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Taiwan Liposome Company Ltd

Rectal Cancer-Drug Profiles

axalimogene filolisbac-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bavituximab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRLX-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7046-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2256098-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selinexor-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLC-388-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rectal Cancer-Dormant Projects

Rectal Cancer-Product Development Milestones

Featured News & Press Releases

Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting

Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Rectal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Rectal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Rectal Cancer-Pipeline by AbbVie Inc, H2 2017

Rectal Cancer-Pipeline by Advaxis Inc, H2 2017

Rectal Cancer-Pipeline by Eisai Co Ltd, H2 2017

Rectal Cancer-Pipeline by GlaxoSmithKline Plc, H2 2017

Rectal Cancer-Pipeline by Karyopharm Therapeutics Inc, H2 2017

Rectal Cancer-Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Rectal Cancer-Pipeline by NewLink Genetics Corp, H2 2017

Rectal Cancer-Pipeline by Peregrine Pharmaceuticals Inc, H2 2017

Rectal Cancer-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Rectal Cancer-Pipeline by Taiwan Liposome Company Ltd, H2 2017

Rectal Cancer-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AbbVie Inc

Advaxis Inc

Eisai Co Ltd

GlaxoSmithKline Plc

Karyopharm Therapeutics Inc

Madrigal Pharmaceuticals Inc.

NewLink Genetics Corp

Peregrine Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Taiwan Liposome Company Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person